Guideline Updates and Real-World Experiences in CLL: State-of-the-Art Evidence and Next Questions
The goal of this activity is to improve the knowledge, confidence, and performance of learners to integrate recent findings into the treatment of patients with CLL/SLL.
Updates in the Management of CLL/SLL: Management of Relapsed/Refractory Disease and the Role of Minimal Residual Disease
The therapeutic landscape of chronic lymphocytic leukemia (CLL) has evolved significantly in recent years, and the use of targeted therapy with small molecule inhibitors in the first-line setting will significantly alter the management of relapsed/refractory disease.
Application of Individualized Treatment for CLL/SLL: Novel Agents, Combinations, and Sequencing Therapy

The goal of this activity is to improve the competence and performance of learners to apply practice-changing clinical data and expert recommendations to optimize the use current/emerging therapeutic strategies in the care of their patients with CLL/SLL.

 

Application of Individualized Treatment for CLL/SLL: Novel Agents, Combinations, and Sequencing Therapy

The goal of this activity is to improve the competence and performance of learners to apply practice-changing clinical data and expert recommendations to optimize the use current/emerging therapeutic strategies in the care of their patients with CLL/SLL.

 

Chronic Lymphocytic Leukemia Patient Management Simulator

Recent advances in understanding the biology of chronic lymphocytic leukemia (CLL) have resulted in the development of novel therapies targeting key signaling pathways involved in the pathogenesis of this disease.

Archived Monthly Oncology Tumor Boards: A Multidisciplinary Approach to Individualized Patient Care - Chronic Lymphocytic Leukemia
The management of histologic transformation of CLL to aggressive lymphomas remains an unmet clinical need since the standard of care is not established. Treatment selection for patients with CLL without del(17p)/TP53 mutation should be individualized based patient’s age, performance status, comorbid conditions, as well as the agent’s toxicity profile. Oncologists and hematologists need to understand the unique challenges associated with the management of histologic transformation of CLL.
Monthly Oncology Tumor Boards: A Multidisciplinary Approach to Individualized Patient Care - Chronic Lymphocytic Leukemia
The management of histologic transformation of CLL to aggressive lymphomas remains an unmet clinical need since the standard of care is not established. Treatment selection for patients with CLL without del(17p)/TP53 mutation should be individualized based patient’s age, performance status, comorbid conditions, as well as the agent’s toxicity profile. Oncologists and hematologists need to understand the unique challenges associated with the management of histologic transformation of CLL.
Debate - What is Optimal First-Line Therapy for Chronic Lymphocytic Leukemia: Chemoimmunotherapy or Small Molecule Inhibitor Therapy?
The treatment landscape of first-line therapy for chronic lymphocytic leukemia (CLL) has evolved significantly in recent years. Educating the clinicians about the recent clinical advances and the benefits/risks associated with the use of chemoimmunotherapy vs. targeted therapy can help them to make informed clinical decisions and develop an individualized treatment plan.
Approaches to Personalized Treatment for CLL: Expert Guidance on Sequencing Therapy and Novel Agents
The goal of this program is to improve the knowledge and competence of clinicians to implement best practices in the treatment of CLL.
Approaches to Personalized Treatment for CLL: Expert Guidance on Sequencing Therapy and Novel Agents

The goal of this program is to improve the knowledge and competence of clinicians to implement best practices in the treatment of CLL.

 

Provided by the National Comprehensive Cancer Network in collaboration with Clinical Care Options, LLC

Pages

Subscribe to RSS - Chronic Lymphocytic Leukemia